메뉴 건너뛰기




Volumn 70, Issue 13, 2013, Pages 1163-1166

Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG COMBINATION; ISOTONIC SOLUTION; PENICILLANIC ACID; PIPERACILLIN;

EID: 84891406482     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120409     Document Type: Article
Times cited : (14)

References (24)
  • 1
    • 33748092560 scopus 로고    scopus 로고
    • Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: Insights from the Society of Infectious Diseases Pharmacists
    • Lodise TP Jr, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006; 26:1320-32.
    • (2006) Pharmacotherapy , vol.26 , pp. 1320-1332
    • Lodise, T.P.1    Lomaestro, B.M.2    Drusano, G.L.3
  • 2
    • 0031952586 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    • Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26:1-12.
    • (1998) Clin Infect Dis , vol.26 , pp. 1-12
    • Craig, W.A.1
  • 3
    • 0031856680 scopus 로고    scopus 로고
    • The pharmacodynamics of beta-lactams
    • Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998; 27:10-22.
    • (1998) Clin Infect Dis , vol.27 , pp. 10-22
    • Turnidge, J.D.1
  • 4
    • 33845696211 scopus 로고    scopus 로고
    • Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
    • Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007; 44:79-86.
    • (2007) Clin Infect Dis , vol.44 , pp. 79-86
    • Ambrose, P.G.1    Bhavnani, S.M.2    Rubino, C.M.3
  • 5
    • 0036239018 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam
    • Kim MK, Capitano B, Mattoes HM et al. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy. 2002; 22:569-77.
    • (2002) Pharmacotherapy , vol.22 , pp. 569-577
    • Kim, M.K.1    Capitano, B.2    Mattoes, H.M.3
  • 6
    • 33746353088 scopus 로고    scopus 로고
    • Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens
    • Scheetz MH, Hurt KM, Noskin GA et al. Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am J Health-Syst Pharm. 2006; 63:1346-60.
    • (2006) Am J Health-Syst Pharm , vol.63 , pp. 1346-1360
    • Scheetz, M.H.1    Hurt, K.M.2    Noskin, G.A.3
  • 7
    • 70449732715 scopus 로고    scopus 로고
    • Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients
    • Shea KM, Cheatham SC, Smith DW et al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother. 2009; 43:1747-54.
    • (2009) Ann Pharmacother , vol.43 , pp. 1747-1754
    • Shea, K.M.1    Cheatham, S.C.2    Smith, D.W.3
  • 8
    • 11244334599 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation
    • Lomaestro B, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother. 2005; 49:461-3.
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 461-463
    • Lomaestro, B.1    Drusano, G.L.2
  • 9
    • 9644268224 scopus 로고    scopus 로고
    • Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation
    • Lodise TP Jr, Lomaestro B, Rodvold KA et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother. 2004; 48:4718-24.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 4718-4724
    • Lodise, T.P.1    Lomaestro, B.2    Rodvold, K.A.3
  • 10
    • 35848946597 scopus 로고    scopus 로고
    • Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: Prolonged or continuous infusion?
    • Kim A, Sutherland CA, Kuti JL et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy. 2007; 27:1490-7.
    • (2007) Pharmacotherapy , vol.27 , pp. 1490-1497
    • Kim, A.1    Sutherland, C.A.2    Kuti, J.L.3
  • 11
    • 2142660223 scopus 로고    scopus 로고
    • Application of pharmacokinetics and pharmacodynamics to antibiotic selection
    • Ebert SC. Application of pharmacokinetics and pharmacodynamics to antibiotic selection. P&T. 2004; 29:244-53.
    • (2004) P&T , vol.29 , pp. 244-253
    • Ebert, S.C.1
  • 12
    • 78650276164 scopus 로고    scopus 로고
    • Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients
    • Cheatham SC, Shea KM, Healy DP et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents. 2011; 37:46-50.
    • (2011) Int J Antimicrob Agents , vol.37 , pp. 46-50
    • Cheatham, S.C.1    Shea, K.M.2    Healy, D.P.3
  • 13
    • 33846442436 scopus 로고    scopus 로고
    • Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy
    • Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44:357-63.
    • (2007) Clin Infect Dis , vol.44 , pp. 357-363
    • Lodise, T.P.1    Lomaestro, B.2    Drusano, G.L.3
  • 14
    • 79961104396 scopus 로고    scopus 로고
    • The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: A multicenter study
    • Yost RJ, Cappelletty DM, for the RECEIPT Study Group. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy. 2011; 31:767-75.
    • (2011) Pharmacotherapy , vol.31 , pp. 767-775
    • Yost, R.J.1    Cappelletty, D.M.2
  • 15
    • 60349101365 scopus 로고    scopus 로고
    • Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii
    • Letter
    • Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2009; 33:290-1. Letter.
    • (2009) Int J Antimicrob Agents , vol.33 , pp. 290-291
    • Wang, D.1
  • 16
    • 7444246084 scopus 로고    scopus 로고
    • Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts
    • Kotapati S, Nicolau DP, Nightingale CH et al. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health-Syst Pharm. 2004; 61:1264-70.
    • (2004) Am J Health-Syst Pharm , vol.61 , pp. 1264-1270
    • Kotapati, S.1    Nicolau, D.P.2    Nightingale, C.H.3
  • 17
    • 55949093232 scopus 로고    scopus 로고
    • Trends in antibacterial use in US academic health centers
    • Pakyz AL, MacDougall C, Oinonen M et al. Trends in antibacterial use in US academic health centers. Arch Intern Med. 2008; 168:2254-60.
    • (2008) Arch Intern Med , vol.168 , pp. 2254-2260
    • Pakyz, A.L.1    MacDougall, C.2    Oinonen, M.3
  • 19
    • 0028208648 scopus 로고
    • Compatibility of piperacillin sodium plus tazobactam sodium with selected drugs during simulated Y-site injection
    • Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam sodium with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1994; 51:672-8.
    • (1994) Am J Hosp Pharm , vol.51 , pp. 672-678
    • Trissel, L.A.1    Martinez, J.F.2
  • 20
    • 0032470573 scopus 로고    scopus 로고
    • Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration
    • Trissel LA, Gilbert DL. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm. 1998; 33:1515-22.
    • (1998) Hosp Pharm , vol.33 , pp. 1515-1522
    • Trissel, L.A.1    Gilbert, D.L.2
  • 21
    • 78049244903 scopus 로고    scopus 로고
    • Importance of infusion volume and pump characteristics in extended administration of beta-lactam antibiotics
    • Claus B, Buyle F, Robays H et al. Importance of infusion volume and pump characteristics in extended administration of beta-lactam antibiotics. Antimicrob Agents Chemother. 2010; 54:4950.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 4950
    • Claus, B.1    Buyle, F.2    Robays, H.3
  • 22
    • 0017399410 scopus 로고
    • Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets
    • Allen LV Jr, Levinson RS, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34:939-43.
    • (1977) Am J Hosp Pharm , vol.34 , pp. 939-943
    • Allen, L.V.1    Levinson, R.S.2    Phisutsinthop, D.3
  • 23
    • 84949151504 scopus 로고    scopus 로고
    • I.V. compatibility results
    • Greenwood Village, CO: Thomson Healthcare. Updated periodically
    • I.V. compatibility results. In: Micromedex Healthcare Series (Internet database). Greenwood Village, CO: Thomson Healthcare. Updated periodically.
    • Micromedex Healthcare Series (Internet Database)
  • 24
    • 44049095124 scopus 로고    scopus 로고
    • Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides
    • Desai NR, Shah SM, Cohen J et al. Zosyn (piperacillin/tazobactam) reformulation: expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides. Ther Clin Risk Manag. 2008; 4:303-14.
    • (2008) Ther Clin Risk Manag , vol.4 , pp. 303-314
    • Desai, N.R.1    Shah, S.M.2    Cohen, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.